GSK Aug 2024 29.000 put
| Previous close | 0.0600 |
| Open | 0.0600 |
| Bid | 0.0500 |
| Ask | 0.1500 |
| Strike | 29.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.0600 - 0.0600 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
BenzingaZantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
A Chicago jury rejected an Illinois woman’s claim that the discontinued heartburn drug Zantac caused her colon cancer. This case is the first of thousands of similar lawsuits. The jury in Cook County, Illinois, found that Angela Valadez, an 89-year-old Illinois resident, did not prove her cancer was linked to her Zantac use. Related: GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims. Valadez alleged that her cancer resulted from taking over-the-
Fool.co.ukUK stocks are hitting all-time highs! Yet these 2 still look cheap to me
The FTSE 100's on a roll. But it's still possible to pick bargain UK stocks, provided we know where to look, says Harvey Jones The post UK stocks are hitting all-time highs! Yet these 2 still look cheap to me appeared first on The Motley Fool UK.
BenzingaGSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
GSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure, accusing the pharmaceutical giant of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, once a blockbuster heartburn drug. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. In a whistleblower complaint filed on Monday, Valisure claimed GSK violated the federal False Claims Act by hid
